SCHEMBL4370293

SCHEMBL4370293

NC(=O)c1ccc(Cl)cc1Cl.O=S(=O)(O)c1ccc(N2CCCC2)nc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.47
ALDH1A1 P00352 4/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
L3MBTL1 Q9Y468 3/20 0.44
GAA P10253 3/20 0.44
HSD17B10 Q99714 2/20 0.44
CNR2 P34972 2/20 0.43
MEN1 O00255 2/20 0.42
ATM Q13315 1/20 0.41
KDM4E B2RXH2 2/20 0.41
CHRNA7 P36544 1/20 0.41
CA12 O43570 2/20 0.40
CA1 P00915 2/20 0.40
CA2 P00918 2/20 0.40
CA4 P22748 2/20 0.40
CA7 P43166 2/20 0.40
CA9 Q16790 2/20 0.40
CCR9 P51686 1/20 0.40
LMNA P02545 1/20 0.40
PKM P14618 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4371258 0.99 KMT2A (0.49) KMT2AALDH1A1SMN1; SMN2L3MBTL1GAA
SCHEMBL4368494 0.90 ALDH1A1 (0.44) KMT2AALDH1A1L3MBTL1GAAHSD17B10
SCHEMBL4370241 0.90 ALDH1A1 (0.58) KMT2AALDH1A1SMN1; SMN2L3MBTL1GAA
SCHEMBL4368487 0.89 KMT2A (0.46) KMT2AALDH1A1SMN1; SMN2L3MBTL1GAA
SCHEMBL1885482 0.89 KMT2A (0.47) KMT2AALDH1A1L3MBTL1GAAMEN1
SCHEMBL4379844 0.89 KMT2A (0.46) KMT2AALDH1A1SMN1; SMN2CA12CA1
SCHEMBL1891065 0.89 HSD17B10 (0.53) KMT2AALDH1A1SMN1; SMN2HSD17B10MEN1
SCHEMBL4371350 0.88 KMT2A (0.47) KMT2AALDH1A1SMN1; SMN2L3MBTL1GAA
SCHEMBL4379865 0.87 GAA (0.44) KMT2AALDH1A1SMN1; SMN2GAAKDM4E
SCHEMBL1882731 0.87 ALDH1A1 (0.43) KMT2AALDH1A1L3MBTL1MEN1CCR9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7625896-B2 Pyridylsulfonamide derivatives HOFFMAN-LA ROCHE INC. (US) 2009-12-01 US claimed
US-20070123513-A1 6-thiomorpholin-4-yl-pyridine-3-sulfonic acid 4-chloro-2-methoxy-benzoylamide; ammonium salt of3-methyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-sulfonic acid 4-chloro-2-methoxy-benzoylamide; anticarcinogenic agent HOFFMANN-LA ROCHE INC. 2007-05-31 US claimed
US-7625896-B2 Pyridylsulfonamide derivatives HOFFMAN-LA ROCHE INC. (US) 2009-12-01 US disclosed
US-20070123513-A1 6-thiomorpholin-4-yl-pyridine-3-sulfonic acid 4-chloro-2-methoxy-benzoylamide; ammonium salt of3-methyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-sulfonic acid 4-chloro-2-methoxy-benzoylamide; anticarcinogenic agent HOFFMANN-LA ROCHE INC. 2007-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070123513-A1 6-thiomorpholin-4-yl-pyridine-3-sulfonic acid 4-chloro-2-methoxy-benzoylamide; ammonium salt of3-methyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-sulfonic acid 4-chloro-2-methoxy-benzoylamide; anticarcinogenic agent TPMT, BPNT1, SLC6A3 KMT2A 959/4885ALDH1A1 1180/4885SMN1; SMN2 2452/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.